Long before the AI boom, Novonesis began creating structured data repositories in the 2000s to manage high-throughput screening data. This decades-long data discipline is now a massive competitive advantage, providing the clean foundation necessary for effective machine learning and digital twins.

With powerful LLMs, reasoning, and inference becoming commoditized, the key differentiator for AI-powered products is no longer the model itself. The most critical factor for success is the quality of the underlying data. Unifying, protecting, and ensuring the accessibility of high-quality data is the primary challenge.

Companies invest heavily in data but struggle to extract actionable insights. Different business units use disparate data sets, leading to conflicting signals and preventing cohesive, enterprise-wide commercial strategies. The goal is to find the "signal" in the "noise."

The most effective CRO partnerships transcend a simple client-vendor dynamic. Success hinges on viewing the CRO as an integrated part of the research team, fostering close collaboration in study design and maintaining open, continuous communication.

The unreliability of traditional data sources is breaking down organizational silos. Business leaders are now required to become more technically fluent, asking deep questions about data integrity, while tech teams must translate their work into clear business cases, leading to a convergence of roles.

To avoid unproductive, subjective disagreements, the CEO and CRO must center their interactions on shared, objective data. This data-first approach fosters alignment and ensures conversations are focused on performance, not personal opinions.

Claire Smith envisions a new biotech business model focused on aggregating vast, unstructured health data (genomic, clinical notes) to sell high-value insights to pharma. This "Palantir-style" approach turns data into a scalable product for target identification or patient stratification, avoiding the traditional drug development path.

A CRO's primary role isn't managing today's revenue but architecting the engine for tomorrow's growth. This requires placing creative, long-term bets on new markets, products, and channels—like government sales—even if they don't generate immediate revenue, to ensure future acceleration.

For smaller biotechs, the key to a successful CRO relationship is treating them as a genuine partner. This requires moving beyond a transactional, fear-based dynamic to one of open communication and mutual respect. Biotechs should actively solicit CRO feedback, as they possess valuable cross-industry insights and can identify sponsor-side behaviors that need to change.